Join Vir Biotechnology senior management and a leading hepatologist for an investor conference call, to discuss preliminary data from the Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of chronic hepatitis delta.

The update will include new data on participants that have reached 12 and 24 weeks of chronic suppressive treatment and 48-week data on the efficacy and safety of tobevibart and elebsiran for participants that were previously reported on at the 2023 AASLD meeting.

A live analyst question and answer session will follow the formal presentation.